Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 401–500 of 998

Statins in community acquired pneumonia: Evidence from experimental and clinical studies
Chalmers, J. D., Short, P. M., Mandal, P., Akram, A. R., & Hill, A. T. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.04.005 · Cited by 78
C-Reactive Protein as a Risk Predictor
Albert, M. A., & Ridker, P. M. (2006) · Circulation · doi:10.1161/circulationaha.106.613570 · Cited by 77
Self-citation
Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients
Sager, P. T., Capece, R., Lipka, L., Strony, J. T., Yang, B., Suresh, R., Mitchel, Y., & Veltri, E. P. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.021 · Cited by 77
Statin Use and Fracture Risk
Scranton, R. E., Young, M., Lawler, E. V., Solomon, D. H., GAGNON, D. R., & Gaziano, J. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.17.2007 · Cited by 76
Locking a Leukocyte Integrin with Statins
Frenette, P. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111083451911 · Cited by 77
Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?
Ridker, P. M., Köenig, W., Kastelein, J. J. P., Mach, F., & Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy723 · Cited by 80
Self-citation
Functional Foods: Opportunities & Challenges
Clydesdale, F. M. (2004) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · Cited by 85
Proteína C reativa de alta sensibilidade como biomarcador de risco na doença coronária
Silva, D., & de Lacerda, A. P. (2012) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2012.02.018 · Cited by 74
The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure
Gürgün, C., Ildızlı, M., Yavuzgil, O., Sin, A. Z., Apaydın, A. Z., Çınar, C. S., & Kültürsay, H. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.11.152 · Cited by 75
Baseline Red Blood Cell Distribution Width as a Predictor of Stroke Occurrence and Outcome: A Comprehensive Meta-Analysis of 31 Studies
Song, S., Hua, C., Dornbors, D., Kang, R.-J., Zhao, X., Du, X., He, W., Ding, Y., & Meng, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01237 · Cited by 75
Prospects for Personalized Cardiovascular Medicine
Ginsburg, G. S., Donahue, M., & Newby, L. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.075 · Cited by 72
Evidence for C-Reactive Protein's Role in (CRP) Vascular Disease: Atherothrombosis, Immuno-Regulation and CRP
Mazer, S. P., & Rabbani, L. E. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000037664.77460.d8 · Cited by 75
Direct comparison of dietary portfolio vs statin on C-reactive protein
Jenkins, D. J. A., Kendall, C. W. C., Marchie, A., Faulkner, D. A., Josse, A. R., Wong, J. M., de Souza, R. J., Emam, A., Parker, T. L., Li, T. J., et al. (2005) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602152 · Cited by 74
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia
Kinlay, S., Timms, T., Clark, M., Karam, C., Bilodeau, T., Ridker, P. M., Rifai, N., Carlson, W., Lloyd‐Jones, D. M., Johnstone, M. T., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02306-8 · Cited by 74
Self-citation
C‑reactive protein and cardiovascular disease: From animal studies to the clinic (Review)
Fu, Y., Wu, Y., & Liu, E. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8840 · Cited by 77
Prospective Coronary Heart Disease Screening in Asymptomatic Hodgkin Lymphoma Patients Using Coronary Computed Tomography Angiography: Results and Risk Factor Analysis
Girinsky, T., M’kacher, R., Lessard, N., Koscielny, S., Elfassy, E., Raoux, F., Carde, P. P., Santos, M. A., Margainaud, J.-P., Sabatier, L., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.01.021 · Cited by 75
Statins and biomarkers of inflammation
Devaraj, S., Rogers, J., & Jialal, I. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693938 · Cited by 74
Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance
Biasucci, L. M., Biasillo, G., & Stefanelli, A. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.277 · Cited by 73
C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?
Lavie, C. J., Milani, R. V., Verma, A., & O’Keefe, J. H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181c61b66 · Cited by 72
Pitavastatin: An overview
Saito, Y. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70886-8 · Cited by 73
Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents
Singh, U. S., Tabibian, J. H., Venugopal, S. K., Devaraj, S., & Jialal, I. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.056093 · Cited by 72
Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis
Xiong, X., Chi, J., & Gao, Q. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00284-9 · Cited by 72
Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals
Verma, S., WANG, C., Lonn, E., Charbonneau, F., Buithieu, J., Title, L. M., FUNG, M., Edworthy, S. M., Robertson, A. D., & ANDERSON, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.039 · Cited by 71
HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size
Yamakuchi, M., Greer, J. J. M., Cameron, S. J., Matsushita, K., Morrell, C. N., Fox-Talbot, K., Baldwin, W. M., Lefer, D. J., & Lowenstein, C. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170229.49776.81 · Cited by 71
New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery
Bauer, S. M., Cayne, N. S., & Veith, F. J. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.08.087 · Cited by 70
Efficacy of Locally Delivered 1.2% Rosuvastatin Gel To Non‐Surgical Treatment of Patients With Chronic Periodontitis: A Randomized, Placebo‐Controlled Clinical Trial
Pradeep, A. R., Karvekar, S., Nagpal, K., Patnaik, K., Guruprasad, C. N., & Kumaraswamy, K. M. (2015) · Journal of Periodontology · doi:10.1902/jop.2015.140631 · Cited by 70
Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients
Andreucci, V. E., Fissell, R. B., Bragg‐Gresham, J. L., Ethier, J. H., Greenwood, R. N., Pauly, M. V., Wizemann, V., & Port, F. K. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)01107-2 · Cited by 68
Statins for Stroke Prevention
Amarenco, P., & Tonkin, A. M. (2004) · Circulation · doi:10.1161/01.cir.0000131518.25959.8f · Cited by 70
Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults
Erlinger, T. P., Tarver-Carr, M. E., Powe, N. R., Appel, L. J., Coresh, J., Eberhardt, M. S., & Brancati, F. L. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00650-4 · Cited by 69
High Sensitivity C-reactive Protein: An Emerging Role in Cardiovascular Risk Assessment
Benzaquen, L. R., Yu, H., & Rifai, N. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795556 · Cited by 68
Self-citation
Controversies in stable coronary artery disease
Opie, L. H., Commerford, P., & Gersh, B. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67927-0 · Cited by 69
Statin Inhibition of Fc Receptor–Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol
Loike, J. D., Shabtai, D., Neuhut, R., Malitzky, S., lu, E. E. A., Husemann, J., Goldberg, I. J., & Silverstein, S. C. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000143858.15909.29 · Cited by 69
C-Reactive Protein and Ischemia in Users and Nonusers of β-Blockers and Statins
Beattie, M. S., Shlipak, M. G., Liu, H., Browner, W. S., Schiller, N. B., & Whooley, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000044387.23578.e9 · Cited by 69
Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells
Walter, D. H., Zeiher, A. M., & Dimmeler, S. (2004) · Coronary Artery Disease · doi:10.1097/01.mca.0000131572.14521.8a · Cited by 68
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67
Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus
Matsumoto, K., Sera, Y., Abe, Y., Ueki, Y., Tominaga, T., & Miyake, S. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00198-9 · Cited by 67
Comparison of the effects of 52 weeks weight loss with either a high-protein or high-carbohydrate diet on body composition and cardiometabolic risk factors in overweight and obese males
Wycherley, T. P., Brinkworth, G. D., Clifton, P. M., & Noakes, M. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2012.11 · Cited by 71
Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice
Tuñón, J., Bäck, M., Badimón, L., Bochaton‐Piallat, M., Cariou, B., Daemen, M. J. A. P., Egido, J., Evans, P. C., Francis, S., Ketelhuth, D. F. J., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318773384 · Cited by 70
Systemic Inflammation as a Cardiovascular Disease Risk Factor and as a Potential Target for Drug Therapy
Kaplan, R. C., & Frishman, W. H. (2001) · Heart Disease · doi:10.1097/00132580-200109000-00009 · Cited by 67
Lipaemia, Inflammation and Atherosclerosis
van Oostrom, A. J. H. H. M., van Wijk, J. P. H., & Cabezas, M. C. (2004) · Drugs · doi:10.2165/00003495-200464002-00004 · Cited by 67
Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?
Kushner, I., & Sehgal, A. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.8.867 · Cited by 67
Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA
Park, C. S., Ihm, S., Yoo, K., Kim, D., Lee, J. M., Kim, H.-Y., Chung, W.-S., Seung, K. B., & Kim, J.-H. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.045 · Cited by 66
By Jove! What Is a Clinician to Make of JUPITER?
Kaul, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.189 · Cited by 65
Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen
Siegel, A. J., Mendelson, J. H., Sholar, M. B., McDonald, J. C., Lewandrowski, K. B., Lewandrowski, E. L., Lipinska, I., Ridker, P. M., & Tofler, G. H. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02289-0 · Cited by 66
Self-citation
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 67
Self-citation
Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention
Perreault, S., Ellia, L., Dragomir, A., Côté, R., Blais, L., Bérard, A., & Lalonde, L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.032 · Cited by 66
Long-term effects of birth weight and breastfeeding duration on inflammation in early adulthood
McDade, T. W., Metzger, M. W., Chyu, L., Duncan, G. J., Garfield, C. F., & Adam, E. K. (2014) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2013.3116 · Cited by 67
Protection of Endothelial Function: Targets for Nutritional and Pharmacological Interventions
Sudano, I., Spieker, L. E., Hermann, F., Flammer, A. J., Corti, R., Noll, G., & scher, T. F. L. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200606001-00008 · Cited by 65
The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions
Belay, B., Belamarich, P. F., & Tom-Revzon, C. (2007) · PEDIATRICS · doi:10.1542/peds.2006-0787 · Cited by 66
Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events
Ridker, P. M., Shih, J., Cook, T. J., Clearfield, M. B., Downs, J. R., Pradhan, A. D., Weis, S., & Gotto, A. M. (2002) · Circulation · doi:10.1161/01.cir.0000014447.06099.fb · Cited by 65
Self-citation
Reduction of C-reactive protein levels through use of a multivitamin
Church, T. S., Earnest, C. P., Wood, K., & Kampert, J. B. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.024 · Cited by 65
Emerging families of biomarkers for coronary artery disease: inflammatory mediators
Yayan, J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s45704 · Cited by 64
Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk
Ridker, P. M., MacFadyen, J. G., Nordestgaard, B. G., Köenig, W., Kastelein, J. J. P., Genest, J. J., & Glynn, R. J. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.938118 · Cited by 64
Self-citation
The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry
Kuroda, M., Otake, H., Shinke, T., Takaya, T., Nakagawa, M., Osue, T., Taniguchi, Y., Iwasaki, M., Nishio, R., Kinutani, H., et al. (2016) · EuroIntervention · doi:10.4244/eijy15m12_05 · Cited by 64
C-Reactive Protein: A Novel Marker of Cardiovascular Risk
Shah, S. H., & Newby, L. K. (2003) · Cardiology in Review · doi:10.1097/01.crd.0000077906.74217.6e · Cited by 64
The inflammation: Lipoprotein cycle
Barter, P. J. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.02.004 · Cited by 64
Interrelationship of Free Oxygen Radicals and Endothelial Dysfunction--Modulation by Statins
Waßmann, S., & Nickenig, G. (2003) · Endothelium · doi:10.1080/10623320303357 · Cited by 64
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials
Braunwald, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr310 · Cited by 64
Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress
Martin, N. J., Collier, A. C., Bowen, L. D., Pritsos, K. L., Goodrich, G. G., Arger, K., Cutter, G., & Pritsos, C. A. (2008) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.09.009 · Cited by 63
Global Analysis of RNA Expression Profile in Human Vascular Cells Treated with Statins
Morikawa, S., Takabe, W., Mataki, C., Wada, Y., Izumi, A., Saitō, Y., Hamakubo, T., & Kodama, T. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.62 · Cited by 63
Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin Therapy
Lee, K. K., Cipriano, L. E., Owens, D. K., Go, A. S., & Hlatky, M. A. (2010) · Circulation · doi:10.1161/circulationaha.110.947960 · Cited by 63
Inflammation and atherosclerosis
Shishehbor, M. H., & Bhatt, D. L. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0102-x · Cited by 63
Inflammatory Biomarkers, Statins, and the Risk of Stroke
Ridker, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000017822.82512.62 · Cited by 63
Self-citation
Combating Inflammation in Cardiovascular Disease
Sethwala, A., Goh, I. Y., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.003 · Cited by 68
Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials
Li, H., Wang, C., Liu, C., Li, R., Zou, M., & Cheng, G. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0164-5 · Cited by 62
Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease
Karalis, D. G. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60544-2 · Cited by 61
Inflammatory markers in depressed post-myocardial infarction patients
Schins, A., Tulner, D. M., Lousberg, R. L., Kenis, G., Joris, D., Harry, J. C., Grauls, G., Stassen, F. R. M., Maes, M. H. J., & Honig, A. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.05.009 · Cited by 62
The vascular risk associations with migraine: Relation to migraine susceptibility and progression
Hamed, S. A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.016 · Cited by 61
Protective effects of quercetin and taraxasterol against H2O2-induced human umbilical vein endothelial cell injury in vitro
Yang, D., LIU, X., Liu, M., CHI, H., LIU, J., & Han, H. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2713 · Cited by 61
White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin
Stewart, R., White, H. D., Kirby, A. C., Heritier, S. R., Simes, R. J., Nestel, P. J., West, M., Colquhoun, D. M., & Tonkin, A. M. (2005) · Circulation · doi:10.1161/01.cir.0000160924.73417.26 · Cited by 61
Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement
Tsubouchi, H., Inoguchi, T., Sonta, T., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H., Utsumi, H., & Nawata, H. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.03.031 · Cited by 61
Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers
Tousoulis, D. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00250-8 · Cited by 60
Pleiotropic Effects of Statins
Marzilli, M. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/1153644-s0-000000000-00000 · Cited by 60
Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
Khurana, S., Gupta, S., Bhalla, H. L., Nandwani, S., & Gupta, V. (2015) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.162011 · Cited by 61
High‐sensitivity serum C‐reactive protein levels in subjects with or without myocardial infarction or periodontitis
Persson, G. R., Pettersson, T., Ohlsson, O., & Renvert, S. (2005) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00648.x · Cited by 60
Why some patients respond poorly to statins and how this might be remedied
Thompson, G. R. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3071 · Cited by 60
Role of Inflammation and Infection in Vascular Disease
Corrado, E., & Novo, S. (2005) · Acta chirurgica Belgica · doi:10.1080/00015458.2005.11679782 · Cited by 60
Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis
Nishtar, S., Wierzbicki, A. S., Lumb, P. J., Lambert‐Hammill, M., Turner, C., Crook, M. A., Mattu, M. A., Shahab, S., Badar, A., Ehsan, A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002595 · Cited by 59
Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases
Mutalub, Y. B., Abdulwahab, M., Mohammed, A., Yahkub, A. M., Al-Mhanna, S. B., Yusof, W., Tang, S. P., Rasool, A. H. G., & Mokhtar, S. S. (2022) · Foods · doi:10.3390/foods11172575 · Cited by 64
From Here to JUPITER
Spatz, E. S., Canavan, M., & Desai, M. M. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.832592 · Cited by 59
Secondary hyperparathyroidism promotes the acute phase response – a rationale for supplemental Vitamin D in prevention of vascular events in the elderly
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.041 · Cited by 59
Novel Insights into Uremic Vascular Calcification: Role of Matrix Gla Protein and Alpha-2-Heremans Schmid Glycoprotein/Fetuin
Ketteler, M., Vermeer, C., Wanner, C., Westenfeld, R., Jahnen‐Dechent, W., & Floege, J. (2002) · Blood Purification · doi:10.1159/000063554 · Cited by 59
C-reactive protein and other markers of inflammation in hemodialysis patients.
Heidari, B. (2013) · Europe PMC (PubMed Central) · Cited by 58
The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Nakou, E. S., Liberopoulos, E. N., Milionis, H. J., & Elisaf, M. (2008) · Current Vascular Pharmacology · doi:10.2174/157016108785909733 · Cited by 57
The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Tabrizi, R., Tamtaji, O. R., Mirhosseini, N. Z., Lankarani, K. B., Akbari, M., Dadgostar, E., Borhani‐Haghighi, A., Peymani, P., Ahmadizar, F., & Asemi, Z. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.010 · Cited by 58
Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease
Berliner, S. A., Rogowski, O., Aharonov, S., Mardi, T., Tolshinsky, T., Rozenblat, M., Justo, D., Deutsch, V. R., Serov, J., Shapira, I., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.05.058 · Cited by 58
Atherosclerosis and inflammation
Farmer, J. A., & Torre‐Amione, G. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0031-5 · Cited by 57
Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin
Evangelista, V., Totani, L., Rotondo, S., Lorenzet, R., Tognoni, G., de Berardis, G., & Nicolucci, A. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-07-0453 · Cited by 64
Lipoprotein (a), Inflammation, and Atherosclerosis
Fusco, S. A. D., Maggioni, A. P., Scicchitano, P., Zuin, M., D’Elia, E., & Colivicchi, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072529 · Cited by 58
The Effect of Different Doses of Micronized 17ss-Estradiol on C-Reactive Protein, Interleukin-6, and Lipids in Older Women
Prestwood, K. M., Unson, C. G., Kulldorff, M., & Cushman, M. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.8.m827 · Cited by 57
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200216421 · Cited by 60
Evidence-Based Risk Stratification to Target Therapies in Acute Coronary Syndromes
Cannon, C. P. (2002) · Circulation · doi:10.1161/01.cir.0000030416.80014.f4 · Cited by 57
Hemoglobin-to-Red-Cell Distribution Width Ratio Is a Novel Predictor of Long-Term Patient Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study
Xiu, W., Zheng, Y., Wu, T., Hou, X., Yang, Y., Ma, Y., & Xie, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.726025 · Cited by 56
Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident stroke in middle-aged and older Chinese adults: a longitudinal analysis based on CHARLS
Yang, Y., & Liu, A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02945-9 · Cited by 60
Do AV Fistulas Contribute to Cardiac Mortality in Hemodialysis Patients?
Dikow, R., Schwenger, V., Zeier, M. G., & Ritz, E. (2002) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2002.00003.x · Cited by 56
History of Discovery
Bowen‐Pope, D. F., & Raines, E. W. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179556 · Cited by 61
Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease
Gotto, A. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.059 · Cited by 56
Self-citation
Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population
Yang, E. Y., Nambi, V., Tang, Z.-Z., Virani, S. S., Boerwinkle, E., Hoogeveen, R. C., Astor, B. C., Mosley, T. H., Coresh, J., Chambless, L. E., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.006 · Cited by 55
Regulatory T cells: Possible mediators for the anti-inflammatory action of statins
Shahbaz, S. K., Sadeghi, M., Koushki, K., Penson, P. E., & Sahebkar, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104469 · Cited by 58
Platelet‐Rich Fibrin With 1.2% Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial
Pradeep, A. R., Garg, V., Kanoriya, D., & Singhal, S. (2016) · Journal of Periodontology · doi:10.1902/jop.2016.160015 · Cited by 55

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks